Athena Countouriotis, Avenzo Therapeutics CEO (website via Nasdaq)
May 26, 2023 10:20 AM EDTUpdated 11:26 AM
Financing
Startups

Ex-Turn­ing Point ex­ecs plan to have their next bet, Aven­zo, on the Nas­daq next sum­mer

Kyle LaHucik

Senior Reporter

The crew at Turn­ing Point Ther­a­peu­tics is back to­geth­er for a new biotech that wants to ac­quire ear­ly-stage on­col­o­gy small mol­e­cules, in­clud­ing an­ti­body drug con­ju­gates …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times